Skip to main content

Animations

VILIP-1 as Diagnostic and Prognostic Biomarker for Parkinson's Disease

Objective/Rationale:             
Novel biomarkers are key for successful clinical development of Parkinson’s therapies. In Alzheimer’s disease the calcium sensing protein VILIP-1 (visinin-like protein 1) was recently established as a biomarker for early Alzheimer’s detection. Following neuronal damage VILIP-1 is released from neurons and penetrates the CSF and blood system. Since VILIP-1-expression is also reduced in Parkinson’s patients, our goal is to test whether CSF and/or blood levels of VILIP-1 can be utilized as a biomarker for progression of Parkinson’s disease.

Project Description:             
Blood and cerebrospinal fluid samples from Parkinson’s and control patients will be obtained from the Paracelsus-Elena-Klinik, Center of Parkinsonism and Movement Disorders, in Kassel. These samples will analyzed for elevated VILIP-1 levels using a sensitive sandwich ELISA utilizing specific antibodies to VILIP-1. In this small proof-of-principle study the ELISA results for VILIP-1 will be compared to current biomarkers, such as synuclein a.

Relevance to Diagnosis/Treatment of Parkinson’s Disease:                     
To this end no prognostic markers are available to identify individuals that are likely to develop Parkinson’s disease, and thus could benefit from early treatment options. Since VILIP-1 was recently established as a diagnostic as well as a prognostic biomarker for early Alzheimer’s detection, it may serve the same function for Parkinson’s disease. We expect to verify this hypothesis using a sensitive sandwich ELISA test for VILIP-1 detection in Parkinson’s cerebrospinal fluid and blood samples. This is a first exploratory approach with advanced PD subjects and neurological controls, which could be, dependent on the outcome, extended to early and de novo PD subjects controls.

Anticipated Outcome:          
The main goal of this research project is to test in a proof-of principle experiment the hypothesis that VILIP-1 levels, as determined by a sensitive sandwich ELISA detection method in CSF and plasma/serum samples, show significant differences between control versus Parkinson’s subjects. This is a first step to determine whether VILIP-1 should be further established as a novel biomarker for diagnosis and progression of Parkinson’s disease.

 


Researchers

  • Karl-Heinz Braunewell, PhD

    Birmingham, AL United States


Discover More Grants

Search by Related Keywords

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.